4.6 Review

The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology

期刊

CELLS
卷 11, 期 23, 页码 -

出版社

MDPI
DOI: 10.3390/cells11233890

关键词

macrophages; cancer therapy; tumour microenvironment; radiotherapy; chemotherapy; immunotherapy; immunogenic cell death; apoptosis macrophage targeting; TAM heterogeneity

资金

  1. Research Foundation Flanders (FWO) [G0B4620N, 30837538]
  2. KU Leuven [C14/19/098, C3/21/037, POR/16/040]
  3. Kom op Tegen Kanker [KOTK/2018/11509/1, KOTK/2019/11955/1]
  4. VLIR-UOS (iBOF) [iBOF/21/048]
  5. Kom op tegen Kanker (Stand up to Cancer)
  6. Flemish cancer society via Emmanuel van der Schueren (EvDS) PhD fellowship [12699]
  7. FWO-SB PhD Fellowship [1S06821N, 1S44123N]
  8. KU Leuven's Postdoctoral mandate grant [PDMT1/21/032]
  9. FWO [1279223N]

向作者/读者索取更多资源

Tumour-associated macrophages (TAMs) play a crucial role in the tumour microenvironment, modulating various pro-tumorigenic and anti-tumorigenic activities, and their interaction with dying cancer cells is important for regulating cancer growth and treatment efficacy.
Tumour-associated macrophages (TAMs) are essential players in the tumour microenvironment (TME) and modulate various pro-tumorigenic functions such as immunosuppression, angiogenesis, cancer cell proliferation, invasion and metastasis, along with resistance to anti-cancer therapies. TAMs also mediate important anti-tumour functions and can clear dying cancer cells via efferocytosis. Thus, not surprisingly, TAMs exhibit heterogeneous activities and functional plasticity depending on the type and context of cancer cell death that they are faced with. This ultimately governs both the pro-tumorigenic and anti-tumorigenic activity of TAMs, making the interface between TAMs and dying cancer cells very important for modulating cancer growth and the efficacy of chemo-radiotherapy or immunotherapy. In this review, we discuss the interface of TAMs with cancer cell death from the perspectives of cell death pathways, TME-driven variations, TAM heterogeneity and cell-death-inducing anti-cancer therapies. We believe that a better understanding of how dying cancer cells influence TAMs can lead to improved combinatorial anti-cancer therapies, especially in combination with TAM-targeting immunotherapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据